Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models

Glioblastoma multiforme (GBM) is the most aggressive brain tumor. The activity of vosaroxin, a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II, was investigated in GBM preclinical models as a single agent and combined with radiotherapy (RT). Vosarox...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2017-05, Vol.8 (18), p.29865-29886
Hauptverfasser:	Gravina, Giovanni Luca, Mancini, Andrea, Mattei, Claudia, Vitale, Flora, Marampon, Francesco, Colapietro, Alessandro, Rossi, Giulia, Ventura, Luca, Vetuschi, Antonella, Di Cesare, Ernesto, Fox, Judith A, Festuccia, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Apoptosis - drug effects Biomarkers Cell Line, Tumor Cell Survival - drug effects Cytokines - metabolism Disease Models, Animal Dose-Response Relationship, Drug Dose-Response Relationship, Radiation Drug Evaluation, Preclinical Female Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma - radiotherapy Humans Leukocytes - drug effects Leukocytes - metabolism Leukocytes - pathology Leukocytes - radiation effects Mice Naphthyridines - chemistry Naphthyridines - pharmacology Necrosis Radiation Tolerance - drug effects Research Paper Survival Rate Thiazoles - chemistry Thiazoles - pharmacology Tumor Burden - drug effects Tumor Burden - radiation effects Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!